002365 On Other Exchanges
Symbol
Exchange
Shenzhen

qianjiang yongan pharm-a (002365) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for QIANJIANG YONGAN PHARM-A (002365)
\

Related News

No related news articles were found.

qianjiang yongan pharm-a (002365) Related Businessweek News

No Related Businessweek News Found

qianjiang yongan pharm-a (002365) Details

Qianjiang Yongan Pharmaceutical Co., Ltd. manufactures and sells taurine in China and internationally. The company was founded in 2001 and is based in Qianjiang, China.

831 Employees
Last Reported Date: 03/27/19
Founded in 2001

qianjiang yongan pharm-a (002365) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

qianjiang yongan pharm-a
Qianjiang Yongan Pharmaceutical Co., Ltd. Announces A Shares 2018 Final Distribution Plan to Be Implemented, Payable on May 27, 2019

Qianjiang Yongan Pharmaceutical Co., Ltd. announced tax included A shares 2018 final distribution plan of CNY 1.00710900 per ten shares to be implemented, payable on May 27, 2019 with record date of May 24, 2019 and ex- date of May 27, 2019.

Qianjiang Yongan Pharmaceutical Co., Ltd. Approves Profit Distribution Plan for 2018

Qianjiang Yongan Pharmaceutical Co., Ltd. at its annual general meeting held on May 14, 2019, approved a profit distribution plan as cash dividend (tax included) of CNY 1.00000000 per ten shares for 2018.

Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, May 14, 2019

Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, May 14, 2019, at 14:30 China Standard Time. Agenda: To approve 2018 work report of the board of directors; to approve 2018 work report of the supervisory committee; to approve 2018 annual report and its summary; to approve 2018 annual accounts; to approve 2018 profit distribution plan; to approve reappointment of audit firm; and to approve risk investment with proprietary funds.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

002365 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002365.
View Industry Companies
 

Industry Analysis

002365

Industry Average

Valuation 002365 Industry Range
Price/Earnings 18.8x
Price/Sales 2.5x
Price/Book 1.6x
Price/Cash Flow 19.0x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact QIANJIANG YONGAN PHARM-A, please visit www.chinataurine.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.